Azienda Ospedaliera Universitaria Senese, Policlinico Santa Maria alle Scotte

Siena 53100

1 studies enrolling now · 12 studies all time

What they study most

Advanced Malignancies, Advanced Solid Tumors, Anhedonia, Carcinoma, Non-Small-Cell Lung, Depressive Disorder, Major, Head and Neck Carcinoma, Squamous Cell, Lymphoma, Metastatic Cholangiocarcinoma, Metastatic Merkel Cell Carcinoma, Myelofibrosis, Myocarditis Acute, Post Essential Thrombocythemia Myelofibrosis

Studies at this site

• MYTHS - MYocarditis THerapy With Steroids — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Running, not enrolling
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
• A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors — Completed
• A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) — Completed
• A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor — Completed
• The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. — Stopped early
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors — Stopped early